Share This Article:

Thrombotic Microangiopathy Induced by Hyperthermal Intraperitoneal Chemotherapy with Mitomycin C

Abstract Full-Text HTML Download Download as PDF (Size:30KB) PP. 173-174
DOI: 10.4236/ss.2011.24037    4,148 Downloads   6,517 Views  


A patient with pseudomyxoma peritonei underwent Hyperthermal Intraperitoneal Chemotherapy (HIPEC) with Mitomycin C after which she developed thrombotic microangiopathy. This syndrome mimicked possi-ble surgical complications. Treatment with plasma exchange resolved the syndrome and the patient recov-ered completely. This is the first description of thrombotic microangiopathy early after a single dose intrap-eritoneal Mitomycin C.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

M. Köksal, R. Ginkel and J. Zijlstra, "Thrombotic Microangiopathy Induced by Hyperthermal Intraperitoneal Chemotherapy with Mitomycin C," Surgical Science, Vol. 2 No. 4, 2011, pp. 173-174. doi: 10.4236/ss.2011.24037.


[1] Baratti D, Kusamura S, Nonaka D, Langer M, Andreola S, Favaro M, et al. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 2008 Feb; 15(2): 526-34.
[2] Yan T, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience. J Clin Oncol 2009 Dec 20; 27(36): 6237-42.
[3] Chua T, Yan T, Saxena A, Morris D. Should the Treatment of Peritoneal Carcinomatosis by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Still be Regarded as a Highly Morbid Procedure?: A Systematic Review of Morbidity and Mortality. [Review]. Ann Sur 2009 Jun; 249(6): 900-7.
[4] Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2001 Sep; 8(5): 286-93.
[5] Zheng XL, Sadler JE. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol 2008; 3: 249-77.
[6] Taylor CM, Machin S, Wigmore SJ, Goodship TH. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol 2010 Jan; 148(1): 37-47.
[7] Zakarija A, Bennett C. Drug-induced thrombotic microangiopathy. Semin Thromb Hemost 2005 Dec; 31(6): 681-90.
[8] Doll DC, Weiss RB, Issell BF. Mitomycin: ten years after approval for marketing. J Clin Oncol 1985 Feb; 3(2): 276-86.
[9] Lesesne JB, Rothschild N, Erickson B, Korec S, Sisk R, Keller J, et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 1989 Jun; 7(6): 781-9.
[10] Ntukidem N, Arce-Lara C, Otterson GA, Kraut E, Cataland S, Bekaii-Saab T. Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials. Cancer Chemother Pharmacol 2009 Jun 9.
[11] Shah R, Beem E, Sautina L, Zharikov SI, Segal MS. Mitomycin- and calcineurin-associated HUS, endothelial dysfunction and endothelial repair: a new paradigm for the puzzle? Nephrol Dial Transplant 2007 Feb; 22(2): 617-20.

comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.